Helen Eshed, MD
Gynecologic Oncology · Austin, TXNPI 1215195516
Payments from drug & device makers
Across 123 payments — averaging $28,630 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3.1M
- Regeneron$330K
- AbbVie$33K
- AstraZeneca$15K
- Genmab U.S., Inc.$12K
- Immunogen, Inc.$275
- plus $895 from 17 others
What the payments were for
- Consulting fees$3,37510%
- Speaking & faculty fees$26,11675%
- Travel & lodging$3,0959%
- Food & beverage$2,2126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 22 | $3,129,763 |
| Regeneron | 13 | $329,896 |
| AbbVie | 32 | $33,458 |
| AstraZeneca | 9 | $14,812 |
| Genmab U.S., Inc. | 4 | $12,436 |
| Immunogen, Inc. | 2 | $275 |
| Incyte Corporation | 11 | $219 |
| Myriad Genetic Laboratories, Inc. | 6 | $162 |
| GSK | 4 | $95 |
| Johnson & Johnson | 4 | $82 |
| Eisai Inc. | 2 | $50 |
| Novartis | 2 | $43 |
| Astellas Pharma US Inc | 2 | $39 |
| Edwards Lifesciences | 1 | $39 |
| Tempus AI, Inc | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Elahere$29,949
How this compares
$3,521,536 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,934 |
| Enoxaparin Sodium | 12 | $1,664 |
| Estradiol | 19 | $1,242 |
| Prednisolone Acetate | 13 | $493 |
| Gabapentin | 62 | $353 |
| Dexamethasone | 36 | $344 |
| Prochlorperazine Maleate | 28 | $342 |
| Letrozole | 22 | $326 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $304 |
| Oxycodone Hcl | 31 | $241 |
| Neomycin Sulfate | 30 | $158 |
| Ondansetron Hcl | 25 | $137 |
| Ondansetron OdtOndansetron | 11 | $133 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $125 |
| Olanzapine | 25 | $104 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Austin
- Michael TenerielloAustin$2.9M
- Lynne KnowlesAustin$1.3M
- Pamela SolimanHouston$30.7M
- Noelle ClovenFort Worth$7.3M
- Christine LeeShenandoah$6.3M
- Antonio Santillan-GomezSan Antonio$4.5M
- Jayanthi LeaDallas$3.9M
- Robert ColemanHouston$3.4M
- Heather PulaskiTyler$2.5M
- David MillerDallas$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.